Dubinett S - Search Results

1

Myeloid suppressor cells and immune modulation in lung cancer.

Srivastava MK, Andersson Å, Zhu L, Harris-White M, Lee JM, Dubinett S, Sharma S. Srivastava MK, et al. Among authors: dubinett s. Immunotherapy. 2012 Mar;4(3):291-304. doi: 10.2217/imt.11.178. Immunotherapy. 2012. PMID: 22401635 Free PMC article. Review.

2

COX-2-dependent stabilization of survivin in non-small cell lung cancer.

Krysan K, Merchant FH, Zhu L, Dohadwala M, Luo J, Lin Y, Heuze-Vourc'h N, Põld M, Seligson D, Chia D, Goodglick L, Wang H, Strieter R, Sharma S, Dubinett S. Krysan K, et al. Among authors: dubinett s. FASEB J. 2004 Jan;18(1):206-8. doi: 10.1096/fj.03-0369fje. Epub 2003 Nov 3. FASEB J. 2004. PMID: 14597555

3

Overexpression of CCL-21/secondary lymphoid tissue chemokine in human dendritic cells augments chemotactic activities for lymphocytes and antigen presenting cells.

Riedl K, Baratelli F, Batra RK, Yang SC, Luo J, Escuadro B, Figlin R, Strieter R, Sharma S, Dubinett S. Riedl K, et al. Among authors: dubinett s. Mol Cancer. 2003 Nov 2;2:35. doi: 10.1186/1476-4598-2-35. Mol Cancer. 2003. PMID: 14613584 Free PMC article.

4

Cyclooxygenase-2-dependent expression of survivin in non-small cell lung cancer.

Krysan K, Dohadwala M, Luo J, Lin Y, Zhu L, Heuze-Vourc'h N, Goodglick L, Merchant F, Seligson D, Pold M, Strieter R, Sharma S, Dubinett S. Krysan K, et al. Among authors: dubinett s. Chest. 2004 May;125(5 Suppl):140S. doi: 10.1378/chest.125.5_suppl.140s. Chest. 2004. PMID: 15136466 No abstract available.

5

Cyclooxygenase 2-dependent expression of survivin is critical for apoptosis resistance in non-small cell lung cancer.

Krysan K, Dalwadi H, Sharma S, Põld M, Dubinett S. Krysan K, et al. Among authors: dubinett s. Cancer Res. 2004 Sep 15;64(18):6359-62. doi: 10.1158/0008-5472.CAN-04-1681. Cancer Res. 2004. PMID: 15374938

6

Cyclooxygenase-2-dependent activation of signal transducer and activator of transcription 3 by interleukin-6 in non-small cell lung cancer.

Dalwadi H, Krysan K, Heuze-Vourc'h N, Dohadwala M, Elashoff D, Sharma S, Cacalano N, Lichtenstein A, Dubinett S. Dalwadi H, et al. Among authors: dubinett s. Clin Cancer Res. 2005 Nov 1;11(21):7674-82. doi: 10.1158/1078-0432.CCR-05-1205. Clin Cancer Res. 2005. PMID: 16278387

7

Oncogenic RAS mutations in myeloma cells selectively induce cox-2 expression, which participates in enhanced adhesion to fibronectin and chemoresistance.

Hoang B, Zhu L, Shi Y, Frost P, Yan H, Sharma S, Sharma S, Goodglick L, Dubinett S, Lichtenstein A. Hoang B, et al. Among authors: dubinett s. Blood. 2006 Jun 1;107(11):4484-90. doi: 10.1182/blood-2005-09-3926. Epub 2006 Feb 23. Blood. 2006. PMID: 16497971 Free PMC article.

8

Towards effective immunotherapy for lung cancer: simultaneous targeting of tumor-initiating cells and immune pathways in the tumor microenvironment.

Dubinett S, Sharma S. Dubinett S, et al. Immunotherapy. 2009 Sep;1(5):721-5. doi: 10.2217/imt.09.56. Immunotherapy. 2009. PMID: 20636013 Free article. No abstract available.

9

MUC1 peptide vaccine mediated antitumor activity in non-small cell lung cancer.

Sharma S, Srivastava MK, Harris-White M, Lee JM, Dubinett S. Sharma S, et al. Among authors: dubinett s. Expert Opin Biol Ther. 2011 Aug;11(8):987-90. doi: 10.1517/14712598.2011.598146. Expert Opin Biol Ther. 2011. PMID: 21711210 Free PMC article.

10

Myeloid suppressor cell depletion augments antitumor activity in lung cancer.

Srivastava MK, Zhu L, Harris-White M, Kar UK, Huang M, Johnson MF, Lee JM, Elashoff D, Strieter R, Dubinett S, Sharma S. Srivastava MK, et al. Among authors: dubinett s. PLoS One. 2012;7(7):e40677. doi: 10.1371/journal.pone.0040677. Epub 2012 Jul 16. PLoS One. 2012. PMID: 22815789 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

292 results

Search Page